BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

Stock Information for BetterLife Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BetterLife Pharma Inc.

BetterLife Advances BETR-001 IND-enabling Studies
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
BetterLife Announces Closing of a Private Placement
BetterLife Announces Extension of Warrants
US Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivatives

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.